ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis

[1]  R. Glynne-Jones,et al.  Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis , 2021, Acta oncologica.

[2]  P. Ding,et al.  Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer , 2021, Journal of Hematology & Oncology.

[3]  J. Ptak,et al.  Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study , 2021, PLoS medicine.

[4]  E. Oki,et al.  CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer , 2021, Cancer science.

[5]  F. D. De Braud,et al.  Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy , 2021, ESMO open.

[6]  B. Bellosillo,et al.  Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial , 2021, Clinical Cancer Research.

[7]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[8]  S. Shchegrova,et al.  Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Huadan Xue,et al.  Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study , 2020, Clinical Cancer Research.

[10]  I. Wistuba,et al.  Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[11]  A. Robidoux,et al.  Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer , 2020, Scientific Reports.

[12]  R. Kurzrock,et al.  Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases , 2020, Annals of Surgical Oncology.

[13]  O. W. Lindwasser,et al.  ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper , 2020, Nature Reviews Clinical Oncology.

[14]  T. Noda,et al.  Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence , 2020, British Journal of Cancer.

[15]  A. Broeks,et al.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.

[16]  R. Scharpf,et al.  White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer , 2020, Nature Communications.

[17]  S. Park,et al.  MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy , 2020, European Radiology.

[18]  C. Andersen,et al.  IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2. Study protocol , 2020, Acta oncologica.

[19]  D. Tait,et al.  MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer , 2019, Clinical Cancer Research.

[20]  D. Moro,et al.  Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Ptak,et al.  Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. , 2019, JAMA oncology.

[22]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[23]  C. Andersen,et al.  Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[25]  X. Yi,et al.  Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing , 2019, Molecular Cancer.

[26]  N. Girard,et al.  Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy , 2018, Nature Reviews Clinical Oncology.

[27]  S. Wexner,et al.  Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection , 2018, JAMA oncology.

[28]  K. Kinzler,et al.  Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study , 2018, Gut.

[29]  N. Baxter,et al.  A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. , 2017, The lancet. Gastroenterology & hepatology.

[30]  H. Nielsen,et al.  Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer , 2017, Clinical Cancer Research.

[31]  G. Guyatt,et al.  Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients , 2015, BMJ : British Medical Journal.

[32]  H. Nielsen,et al.  Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.

[33]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[34]  G. Beets,et al.  MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer , 2014, Nature Reviews Gastroenterology &Hepatology.

[35]  Sarah Burdett,et al.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.

[36]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[37]  J. Stinson,et al.  Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework , 2013, Systematic Reviews.

[38]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[39]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[40]  J. Hartley,et al.  Magnetic resonance imaging accuracy in assessing tumour down‐staging following chemoradiation in rectal cancer , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[41]  D. Treanor,et al.  Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer , 2005, Histopathology.

[42]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[43]  H. Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.

[44]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[45]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[46]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[47]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[48]  Katja Jasinskaja,et al.  Elaboration and Explanation ⋆ , 2011 .

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.